SK海力士(SKHY.O)：预计2027年资本开支将较2026年大幅增加。

SK海力士(SKHY.O)：DRAM和HBM到2029年的产能已全部售罄。

China's National Joint Drug Procurement Office on Oct. 26 revoked the national procurement winning status for letrozole tablets produced by Eugia Pharma Specialities Limited and gadoterate meglumine injection produced by JSC Farmak. The office said both applicants recently reported they could not continue to supply the products and, after supervisory interviews, still failed to meet medical institutions' demand. Eugia and its applicant Hangzhou Ketu Supply Chain Co. were placed on the violations list and barred from participating in national drug procurement for four years; JSC Farmak and its applicant Shanghai Liyi Pharmaceutical Technology Co. were likewise listed and barred for two years.